The current and likely future status of low-LET charged-particle therapy of cancer is reviewed with regard to both physical and clinical aspects. We conclude that such therapy has reached the stage at which clinical implementation is practical and that a broader program is needed if the clinical advantages of improved dose distributions are to be determined